CCL11抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P06312(CCL11 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The CCL11 antibody targets C-C motif chemokine ligand 11 (CCL11), a small signaling protein also known as eotaxin-1. CCL11 belongs to the CC chemokine family and plays a key role in recruiting eosinophils by binding to its receptor CCR3. which is predominantly expressed on eosinophils and some Th2 lymphocytes. It is implicated in allergic and inflammatory diseases, such as asthma, atopic dermatitis, and eosinophilic esophagitis, where excessive eosinophil infiltration contributes to tissue damage. CCL11 is also linked to age-related pathologies, including neurodegeneration, as elevated levels have been observed in aging brains and Alzheimer’s disease models, suggesting a potential role in cognitive decline.

Antibodies against CCL11 are tools for research and therapeutic development. They neutralize CCL11 activity, blocking its interaction with CCR3 to inhibit eosinophil migration and activation. In preclinical studies, CCL11 antibodies have shown promise in reducing inflammation in allergic models and mitigating neuroinflammation. Additionally, they are used in diagnostic assays to measure CCL11 levels in biological samples, aiding in disease monitoring. Recent interest has grown in exploring CCL11's role beyond immunity, particularly its involvement in aging and neurological disorders, positioning these antibodies as potential therapeutics for diverse conditions. However, challenges remain in optimizing specificity and minimizing off-target effects in clinical applications.